- high blood pressure
- high blood sugar
- high grade
- high-dose chemotherapy
- high-dose radiation
- high-dose-rate remote brachytherapy
- high-dose-rate remote radiation therapy
- high-energy photon therapy
- high-grade lymphoma
- high-grade squamous intraepithelial lesion
- high-intensity focused ultrasound therapy
- high-risk cancer
- high-selenium baker's yeast
- high-selenium Brassica juncea
- highly active antiretroviral therapy
- hilar
- Hiltonol
- HIPAA
- histamine
- histamine dihydrochloride
- histiocytic lymphoma
- histologic examination
- histology
- histone
- histone deacetylase
- histone deacetylase inhibitor
- histopathology
- historic cohort study
- historical control subject
- HIV
- HIV antibody
- HIV positive
- hives
- Hivid
- HLA
- HLA-A*0201-restricted TRP2-gp100-EphA2-HER2 multipeptide vaccine
- HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine
- HLA-A*0201-restricted VEGFR1 peptide vaccine
- HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine
- HLA-A*2402-restricted KOC1-TTK-CO16-DEPDC1-MPHOSPH1 multipeptide vaccine
- HLA-A*2402-restricted URLC10 peptides vaccine
- HLA-A*2402-restricted URLC10-CDCA1-VEGFR1-VEGFR2 multipeptide vaccine
- HLA-A*2402-restricted URLC10-KOC1-VEGFR1-VEGFR2 multipeptide vaccine
- HLA-A*2402-restricted URLC10-TTK-KOC1 multipeptide vaccine
- HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine
- HLA-A*2402-restricted VEGFR1 peptide vaccine
- HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine
- HLA-A1, A2, B35-restricted survivin peptides / Montanide ISA-51 vaccine
- HLA-A2, A3-restricted FGF-5 peptides / Montanide ISA-51 vaccine
- HLA-A2-restricted synthetic glioma antigen peptides vaccine